Anthracyclines are cytostatic antibiotics [1] that have been used since the 1970s. These anticancer agents still represent the backbone of many chemotherapy-based strategies with a curative intent in patients with lymphoma, acute leukemia, breast cancer and sarcoma. Due to the broad indication and the spread use in cancer patients, anthracycline-related myocardial toxicity (ARMT), namely the development of left ventricular (LV) dysfunction and cardiac heart failure (CHF), remains a concern [2].
